[Ip-health] Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines

Tahir Amin tahir at i-mak.org
Tue Dec 8 10:27:14 PST 2015


Dear All,


A recent paper (resulting from a study that was done for GAVI), which looks
at IPRs, patent landscapes and the challenges for developing country
vaccine manufacturers for developing new vaccines for HPV, Rotavirus and
Pneumococcal  is now available at the link below:

http://www.sciencedirect.com/science/article/pii/S0264410X15011913
Intellectual property rights and challenges for development of affordable
human papillomavirus, rotavirus and pneumococcal vaccines: Patent
landscaping and perspectives of developing country vaccine manufacturers
Abstract

The success of Gavi, the Vaccine Alliance depends on the vaccine markets
providing appropriate, affordable vaccines at sufficient and reliable
quantities. Gavi's current supplier base for new and underutilized
vaccines, such as the human papillomavirus (HPV), rotavirus, and the
pneumococcal conjugate vaccine is very small. There is growing concern that
following globalization of laws on intellectual property rights (IPRs)
through trade agreements, IPRs are impeding new manufacturers from entering
the market with competing vaccines. This article examines the extent to
which IPRs, specifically patents, can create such obstacles, in particular
for developing country vaccine manufacturers (DCVMs). Through building
patent landscapes in Brazil, China, and India and interviews with
manufacturers and experts in the field, we found intense patenting activity
for the HPV and pneumococcal vaccines that could potentially delay the
entry of new manufacturers. Increased transparency around patenting of
vaccine technologies, stricter patentability criteria suited for local
development needs and strengthening of IPRs management capabilities where
relevant, may help reduce impediments to market entry for new manufacturers
and ensure a competitive supplier base for quality vaccines at sustainably
low prices.

-- 
Tahir Amin
Co-Founder and Director of Intellectual Property
Initiative for Medicines, Access & Knowledge (I-MAK)
*Website:* www.i-mak.org
*Email:* tahir at i-mak.org
*Skype: *tahirmamin
*Tel:* +1 917 455 6601/+44 771 853 9472



More information about the Ip-health mailing list